Joanne Wilson

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 4

Top Topics

Minimally Invasive

Acute Lymphoblastic Leukemia

Top Venues

Cancer research communications

Clinical cancer research : an official journal of the American Association for Cancer Research

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Giulia Dellavedova, Alessandra Decio, Laura Formenti, Mark R Albertella, Joanne Wilson, Anna D Staniszewska, Elisabetta Leo, Raffaella Giavazzi, Carmen Ghilardi, Maria Rosa Bani
The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin. Cancer research communications 3 (3) (2023)
Giulia Dellavedova, Alessandra Decio, Laura Formenti, Mark R Albertella, Joanne Wilson, Anna D Staniszewska, Elisabetta Leo, Raffaella Giavazzi, Carmen Ghilardi, Maria Rosa Bani
The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin. Cancer research communications 3 (3) (2023)
Giuditta Illuzzi, Anna D Staniszewska, Sonja J Gill, Andy Pike, Lisa McWilliams, Susan E Critchlow, Anna Cronin, Stephen E Fawell, Glen Hawthorne, Kunzah Jamal, Jeffrey W Johannes, Emilyanne Leonard, Ruth Macdonald, Gareth A Maglennon, Jenni Nikkilä, Lenka Oplustil O'Connor, Aaron Smith, Harriet Southgate, Joanne Wilson, James W T Yates, Sabina Cosulich, Elisabetta Leo
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (21) (2022)
Balakrishna Koneru, Ahsan S Farooqi, Thinh Hoang Nguyen, Wan Hsi Chen, Ashly Hindle, Cody Eslinger, Monish Ram Makena, Trevor A Burrow, Joanne Wilson, Aaron Smith, Venkatesh Pilla Reddy, Elaine B Cadogan, Stephen T Durant, C Patrick Reynolds
ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156. Science translational medicine 13 (607) (2021)